New drug RP-001 enters human trials for advanced cancers
Disease control
Not yet recruiting
This early-phase study tests a new drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goal is to check safety and find the best dose. Researchers will also watch for any signs that the drug shrinks tumors.
Phase: PHASE1, PHASE2 • Sponsor: Recurv Pharma Inc • Aim: Disease control
Last updated May 16, 2026 15:41 UTC